Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin by Frederiksen, Kit et al.
        
Citation for published version:
Frederiksen, K, Guy, RH & Petersson, K 2015, 'Formulation considerations in the design of topical, polymeric
film-forming systems for sustained drug delivery to the skin', European Journal of Pharmaceutics and
Biopharmaceutics, vol. 91, pp. 9-15. https://doi.org/10.1016/j.ejpb.2015.01.002
DOI:
10.1016/j.ejpb.2015.01.002
Publication date:
2015
Document Version
Peer reviewed version
Link to publication
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
 Page 1 of 27 
 
Frederiksen et al., 2014 submitted to European Journal of Parmaceutics and Biopharmaceutics. 
Formulation considerations in the design of topical, polymeric 
film-forming systems for sustained drug delivery to the skin 
 
Kit Frederiksen1,2, Richard H. Guy2, Karsten Petersson1,* 
 
1 LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark. 
2 University of Bath, Department of Pharmacy & Pharmacology, Claverton Down, Bath, BA2 
7AY, UK. 
 
* Corresponding author: Tel.: +45 4494 5888. E-mail address: karsten.petersson@leo-
pharma.com (Karsten Petersson) 
 
  
 Page 2 of 27 
 
Frederiksen et al., 2014 submitted to European Journal of Parmaceutics and Biopharmaceutics. 
Graphical abstract 
Polymeric film-forming systems (FFS) are potential drug delivery systems for topical applica-
tion to the skin. The FFS form thin and transparent polymeric films in situ upon solvent evap-
oration. Their application convenience and cosmetic attributes, superior to conventional semi-
solids, may offer improved patient compliance. This study represents the first phase of an investi-
gation into the use of FFS for prolonged dermal drug delivery. FFS formulations were distin-
guished based on their ability to sustain the release of betamethasone 17-valerate (BMV) in 
vitro over 72h. The effect of film-forming polymer (hydrophilic: hydroxypropyl cellulose 
(Klucel™ LF); hydrophobic: polymethacrylate copolymers (Eudragit® NE and Eudragit® RS), 
and polyacrylate copolymer (Dermacryl®79) was first determined, and then the impact of in-
corporation of plasticisers (triethyl citrate, tributyl citrate, and dibutyl sebacate) was exam-
ined. The Klucel film released a significantly higher amount of BMV than the hydrophobic 
FFS, 42 versus 4 µg/cm2, respectively. The release was increased when a plasticiser was in-
corporated, and with higher enhancement ratios achieved with the more lipophilic plasticisers. 
In conclusion, the results show that FFS can sustain drug release (hence representing useful 
systems for prolonged dermal therapy) and emphasize the importance of the formulation on 
drug delivery, with the type of polymer being of greatest significance. 
Keywords  
Dermal drug delivery; polymeric film-forming systems; betamethasone 17-valerate; in vitro 
release; plasticiser. 
 
1 Introduction 
Poor patient compliance is a well-known consequence of repetitive daily applications of con-
ventional topical dosage forms, such as ointment, creams or gels, with less attractive cosmetic 
attributes. This is especially pronounced in the treatment of chronic skin diseases (1-4). While 
semi-solid dosage forms may exhibit sustained-release characteristics, they do not always 
ensure persistent contact to the skin for an extended treatment interval. Development of topi-
cal formulations permitting less frequent dosing is therefore of great interest for dermatologi-
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cal therapy. Less frequent dosing may be facilitated by increasing the contact time and/or 
maintaining the delivery of the drug substance to the local site of action by forming a drug 
reservoir in or on the skin. Such an outcome will presumably rely on the composition of the 
formulation. 
While polymeric film-forming systems (FFS) have been used for the transdermal delivery of 
steroidal hormones and analgesics for systemic therapeutic effect (5-11), they also represent 
attractive, alternative topical formulations in dermatology. The anti-fungal agent, terbinafine, 
has been incorporated in a FFS (Lamisil® Once*) for the targeted treatment of dermatophyto-
ses in the stratum corneum (SC), and exemplifies how increasing the drug residence time on 
the skin permits less frequent dosing (12). FFS are applied directly to the skin and form thin, 
transparent films in situ upon solvent evaporation. The drug substance is dissolved in the film-
forming vehicle and thus incorporated in the film formed on the skin. The polymeric network 
of the formed film can function to form an external reservoir and/or limit the supply of drug 
substance to the skin reservoir, and thereby control the release of drug substance (6). Addi-
tionally, FFS may have superior cosmetic attributes to semi-solid formulations, as FFS are 
fast-drying, less greasy and almost invisible once applied on the skin (1).  
Complete skin contact over the entire application period is essential. A successful formulation 
for prolonged delivery would therefore require high flexibility to adapt to the movements of 
the skin, and high substantivity and strong adhesion to the skin for a consistent delivery and 
absorption of the drug (11). These parameters are important to bear in mind during the formu-
lation design process. 
Several factors are likely to affect drug delivery from FFS, including: the drug’s physico-
chemical properties (13-17), the polymer type and its concentration (5;6;18), the plasticiser 
type and its concentration (18-23), the incorporation of other excipients (e.g., a penetration 
enhancer, a lipid component, or a cyclodextrin) (5;24-27), and vehicle metamorphosis post 
application, such as solvent evaporation leading to increase in drug saturation and possibly 
supersaturation (28-32). 
                                               
* Lamisil® Once is a registered trade name of Novartis Consumer Health SA, Nyon, Switzerland 
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The substantivity of a topically applied formulation on the skin, defined as its persistence and 
resistance to removal, e.g. by washing and wear, is crucial for prolonged drug delivery. For 
the formulation to sustain a therapeutic effect, a drug reservoir must be established. The type 
and composition of the vehicle will affect the formation of such a reservoir. For a FFS, the 
polymer’s water solubility is likely to be crucial to the location of this reservoir. Hydrophilic 
film-forming polymers, to be effective, have to establish a drug reservoir in the skin, due to 
their low water-resistance and resulting short-term persistence on the skin. Hydrophobic 
films, having higher water-resistance and substantivity can form an external drug reservoir on 
the skin, as well one within it. 
The aim of the research described here was to initiate an investigation into the potential of FFS to 
provide prolonged dermal drug delivery for the local, topical treatment of skin diseases. In 
contrast to previous work directed to transdermal drug delivery (5;6), this investigation focus-
es on dermal delivery. The earlier work (33) showed that differences in the mechanical prop-
erties of FFS, such as flexibility and abrasion resistance, were indistinguishable when casted 
on glass slides and not, therefore, predictive of the in vivo interface. Here, the in vitro drug 
delivery characteristics of potential FFS are used instead as criteria for further development as 
sustained delivery systems. 
2 Materials and methods 
2.1 Materials 
Betamethasone-17-valerate (BMV, purity 100%) was purchased from Crystal Pharma SAU 
(Boecillo, Spain). The polymers used were Klucel™ LF (Klucel) (hydroxypropyl cellulose) 
provided by Azelis (Lyngby, Denmark), Kollidon® 12 PF/17 PF/25/30 (PVP) (polyvinylpyr-
rolidone of varying molecular weight distributions) from BASF (Germany), Aqualon EC 
N10/N22/N50 (ethyl cellulose) (ethyl cellulose of varying molecular weight distributions, 
Azelis (Lyngby, Denmark), Chitofarm® S /M /L (chitosan) (chitosan of varying molecular 
weight distributions) Cognis GmbH (Germany), and Eudragit® RS PO (Eudragit RS) (am-
monio methacrylate copolymer type B) and Eudragit® NE 40D (Eudragit NE) (poly(ethyl 
acrylate-co-methyl methacrylate) 2:1) from Evonik Röhm GmbH (Darmstadt, Germany). 
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Dermacryl® 79 (Dermacryl) (acrylates/octylacrylamide copolymer) was purchased from Akzo 
Nobel Surface Chemistry AB (Stenungsund, Sweden). Triethyl citrate (TEC) and tributyl cit-
rate (TBC) were from Merck (Darmstadt, Germany), dibutyl sebacate (DBS) from Sigma-
Aldrich (Broendby, Denmark), and methyl-β-cyclodextrin (MbCD) (Kleptose Crysmeb) from 
Roquette (Lestrem, France). Sodium acetate trihydrate and all organic solvents were pur-
chased from VWR – Bie Berntsen A/S (Herlev, Denmark), Merck (Darmstadt, Germany) and 
Sigma-Aldrich (Broendby, Denmark). 
2.2 Preparation of polymeric FFS 
The polymer was dissolved in absolute ethanol (EtOH) (mixed with water for Eudragit RS) 
with or without plasticiser while stirring overnight until a clear solution was obtained. FFS 
compositions tested for in vitro release are in Table 1. BMV was dissolved in the FFS with 
stirring at a concentration of 1.2% w/w (corresponding to 1.0% w/w betamethasone) and pro-
vided an infinite dose for the in vitro release tests. 
The polymer concentration used depended on its type (Table 1). The concentration of plasti-
ciser was 20% w/w relative to the dry weight of the polymer. 
2.3 FFS Characterisation 
2.3.1 Evaluation of FFS formulations 
A range of placebo FFS compositions were evaluated visually (33) using the characteristics 
and ratings described below. The polymer concentration ranges tested were: chitosan (5.0 and 
10.0% w/w), Dermacryl (5.0, 7.5 and 10.0% w/w) ethyl cellulose (5.00 and 10.0% w/w), Eu-
dragit NE (5.0, 7.5 and 10.0% w/w), Eudragit RS (10.0, 15.0, 20.0% w/w), Klucel (2.5, 5.0, 
7.5, 10.0% w/w) and PVP (5.0 and 10.0% w/w).  
FFS vehicle: The appearance of the FFS solutions was assessed as clear or opaque, indicating 
complete or incomplete dissolution of the film-forming polymer, respectively. The viscosity 
was rated as low (equivalent to water), medium (equivalent to glycerol) or high (equivalent to 
Lamisil® Once, marketed cutaneous solution). 
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Polymeric FFS film: Porcine ears were obtained shortly after the animals were killed from 
the Danish Meat Trade College (Roskilde, Denmark). The ears were stored at -20C and 
thawed slowly at 5C before preparation. The ears were cleaned with water, gently trimmed 
with an animal hair clipper (Oster, Tennessee, USA) and used for FFS evaluation within a few 
hours. 
The films were formed either on excised pig ear skin or in a petri dish. 10 µl/cm2 FFS was 
applied and spread within marked areas (3.8 cm2) on the pig skin, while 1000 µl were distrib-
uted across a petri dish (58 cm2), and the solvent allowed to evaporate to form the film. The 
drying time was evaluated 5 minutes after the FFS was applied to the skin by placing a cover 
slide on the film; the film was considered dry if no evidence of humidity was visible on the 
cover slide after removal. 30 minutes after application, the film stickiness was evaluated by 
gently pressing cotton wool onto the dry film. The stickiness was rated according to the quan-
tity of cotton wool retained: low (little or no accumulation), medium (thin layer) or high 
(dense accumulation). 
Film-formation was evaluated and rated as complete/homogeneous, incom-
plete/heterogeneous or with precipitation of the film-forming polymer. The cosmetic attrib-
utes of the film were assessed in terms of structural features as clear, transparent or unclear, 
and as smooth, structured/textured or greasy. Film flexibility was evaluated on the basis of 
cracking, and skin fixation was determined by stretching the skin in 2-3 directions. The film 
was rated flexible (no cracking or skin fixation) or non-flexible (cracking or skin fixation).  
2.3.2 Evaluation of plasticiser incorporation 
Based on the previous experiments, one concentration of each polymer was selected for fur-
ther assessment of the effect of plasticiser incorporation. Three different plasticisers of vary-
ing lipophilicity were considered and their influence on the flexibility and structural features 
of the formed films was assessed visually as described above.  
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2.4 BMV release from polymeric FFS in vitro  
The experiments were conducted using modified diffusion cells (LEO Pharma A/S, Denmark) 
with a silicone membrane (Dow Corning® 7-4107 Silicone Elastomer Membrane, 75µm) 
(Figure 1). A 10% w/w solution of MbCD in acetate buffer pH 4.5 was used as receptor medi-
um to maintain sink conditions (16). The cells were equilibrated for 1 hour in the heating cab-
inet set to maintain a temperature of 32C at the membrane surface thereby mimicking skin 
conditions in vivo. 240 µl FFS were then applied and distributed on the membrane and the 
cells placed with the membrane horizontally in the heating cabinet. The cells were occluded 
with Parafilm® at 95 minutes post-treatment by which time the volatile constituents of the 
FFS had completely evaporated. The cells were then rotated so that the membrane was in the 
vertical position as shown in Figure 1. 
Samples of 1.5 ml were withdrawn after 1, 6, 24, 30, 48, 54 and 72 h, and were replaced with 
the same volume of fresh, preheated receptor medium. The cumulated amount of drug sub-
stance released, Q (corrected for sampling) was calculated as described by Jensen et al. (16). 
2.5 HPLC analysis 
The concentration of BMV in the release samples was quantified by RP-HPLC using a YMC-
Pack ODS-AQ column (YMC Europe GmbH, Germany) at 35C and acetoni-
trile:methanol:acetate buffer pH 4.5 as mobile phase. A flow gradient method was used vary-
ing the ratio of mobile phase A and B, acetonitrile:methanol:acetate buffer pH 4.5 (55:40:5) 
and (5:40:55), respectively, over 10 min, using UV detection at 240nm. A flow rate of 
1.0ml/min and an injection volume of 10µl were applied. The retention time was about 7 min. 
2.6 Dynamic vapour sorption measurements 
Moisture sorption–desorption characteristics of cast films were studied in a dynamic vapour 
sorption apparatus (DVS 1, Surface Measurement Systems, London, UK). All experiments 
were performed at 32°C. Weight changes were determined with an ultra-microbalance (± 0.1 
mg mass resolution).  
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Films of 0.20 (±0.02) mm thickness were casted in a Teflon mold at room temperature. The 
films were dried for 10 hours at 0% relative humidity (RH). Subsequently, stepwise changes 
in RH (0–20-40-60-80-94-80-60-40-20-0%) were imposed and the mass variation over time 
(dm/dt) was monitored to detect when equilibrium sorption/desorption had been attained.  
2.7 Data analysis 
All data were analysed using Graph Pad Prism 5.01. Two-way ANOVA (p < 0.05) followed by 
Bonferroni post-test was applied to compare means.   
 
3 Results 
3.1 Formulation development 
As ethyl cellulose and chitosan were not completely soluble in absolute ethanol, these poly-
mers were eliminated from further investigation. Further, it was observed that PVP films re-
dissolved over the 72 h release experiment, the high hydrophilicity of this polymer resulting 
in substantial moisture sorption. PVP was also excluded, therefore, from further study. The 
visual evaluation of the remaining polymers is summarised in Table 2. 
Increasing polymer concentration increased the viscosity of the solution and its drying time 
for Klucel and Eudragit NE, but such effects were not observed for Eudragit RS and Der-
macryl at the concentrations tested. In general, the FFS compositions formed complete, ho-
mogenous and clear films and exhibit low outward stickiness. Overall, film flexibility de-
creased with increasing polymer concentration. 
Of the FFS compositions that formed clear, fast drying and non-sticky films, 5% Klucel, 7.5% 
Eudragit NE, 15% Eudragit RS and 10% Dermacryl performed the best against the evaluation 
criteria (Table 2) and were selected for further testing. When 20% w/w plasticiser (relative to 
the dry polymer weight) was incorporated into the formulations of all polymers except Eu-
dragit NE, no significant differences in structure and flexibility of the films, relative to those 
without plasticiser, were observed (Table 3). 
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In general, it was not possible to distinguish the influence of the added excipients on the for-
mulations based on the visual evaluation of the FFS and the resulting polymeric film. The 
largest effect of incorporation of plasticiser was observed for the Klucel film, especially with 
the more lipophilic plasticisers TBC and DBS as they formed slightly hazy films. Further, 
while range-finding studies using hyper differential scanning calorimetry showed that the ad-
dition of plasticiser to the FFS lowered the glass transition temperature (Tg) of the formed 
polymeric films (e.g., for 10% Eudragit RS and 15% Eudragit E with TEC at 5-20% and 5-
10%, respectively – data not shown), these findings were not particularly predictive of film 
flexibility on the porcine skin model. 
3.2 In vitro BMV release 
The formulations that adequately satisfied the criteria pertaining to complete film formation 
and cosmetic acceptability (Table 1) were tested for their ability to sustain BMV release in 
vitro over a prolonged period. It was found that all of the tested FFS sustained BMV release 
over 72 hours (Figure 2). The release of the drug from Klucel was highest, corresponding to 
42 μg/cm2 (~3% of the loading), with clear zero-order kinetics (r2 = 1.00; Figure 2, upper 
panel) and no evidence of a lag-time (which might indicate a degree of membrane control). BMV 
release from the hydrophobic films was slower, but showed a classic, ‘burst’ effect (Figure 2, 
lower panel), again contra-indicating any suggestion of membrane control. While there were some 
differences in the drug release profiles observed (due, at least in part, to the different amounts of pol-
ymer used in the formulations and changes in the resulting film thicknesses), the total BMV release 
from the three hydrophobic films in 72 hours was quite consistent (4 µg/cm2 corresponding to 
~0.4%), and further experiments focused only on Eudragit RS as a representative example of 
this type of acrylate polymer.  
The constant release rate of BMV from Klucel was 0.58 μg cm-2 h-1 (r2 = 1.00). The profiles 
for Eudragit NE and RS closely followed a square-root of time (t) dependence, with rates of 
0.50 and 0.45 μg cm-2 h-½, respectively (and both with r2 values of 0.99). BMV release from 
Dermacryl showed a significant “burst” effect over the first 10 hours, after which relatively 
slow, essentially zero-order kinetics were observed.  
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3.2.1 Influence of plasticiser on in vitro release 
The release of BMV from Klucel and Eudragit RS polymeric films containing different plasti-
cisers, of different lipophilicities, was subsequently assessed. For Klucel, the addition of each 
of the plasticisers at 20% w/w enhanced the zero-order release rate of the drug (Figure 3, up-
per panel; r2 = 1.00 for all cases). The rate with DBS was highest (1.67 μg cm-2 h-1), while 
those with TEC and TBC were similar but more modest (1.21 and 1.24 μg cm-2 h-1, respec-
tively). In the case of Eudragit RS, only TBC and DBS significantly increased BMV release 
(p < 0.001), which uniformly followed as before, for the formulation without plasticiser, 
square root of time kinetics (Figure 3, lower panel). The rates of release from the plasticised 
Eudragit films were 0.86, 1.20 and 1.70 μg cm-2 h-½ for TEC, TBC and DBS, respectively 
(again, in all cases, with r2 = 0.99).  
For both polymers, the kinetics of BMV release increased, although not necessarily linearly 
(Figure 4), with the lipophilicity of the plasticiser, as measured by the compounds’ 
log{octanol/water partition coefficient} (log P). 
3.3 Moisture sorption-desorption from polymeric films 
Dynamic vapour sorption was used to characterise moisture sorption in Klucel and Eudragit 
RS films with and without 20% w/w TEC. Water uptake by Klucel was 4 times higher than 
that by Eudragit when the RH of the film’s environment was increased from 0% to 90% at 
32°C. This is consistent with the greater hydrophilicity of Klucel. The sorption and desorption 
isotherms of the Klucel film showed no detectable hysteresis, suggesting that the water was 
not tightly bound and was potentially available to act as a plasticiser. This behaviour was 
completely unchanged by the incorporation of TEC. In contrast, the Eudragit RS film had a 
decreased mass after desorption, perhaps indicative of some solvent entrapment during film 
casting. However, this negative hysteresis was abolished when TEC was incorporated, con-
sistent with its role as an effective plasticiser. 
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4 Discussion 
This investigation has evaluated polymers of hydrophilic and hydrophobic character for their 
potential to be used in film-forming systems (FFS) for prolonged drug delivery applications to 
the skin. Visual assessment indicated that control of the polymer concentration used was es-
sential to avoid creation of thick, brittle films. Equally the viscosity of the FFS has to be se-
lected appropriately to achieve a smooth and complete film (34). It seems likely that lower 
viscosity will be most suitable when designing formulations of the FFS with the caveat, of 
course, that lateral spreading post-deposition be controllable.   
Film flexibility is clearly of importance and a polymer Tg below that of a typical skin surface 
temperature (~32°C) is therefore logical. The polymer, Eudragit NE, has a Tg of 13°C and 
creates flexible films (35). The Tg of Eudragit RS, on the other hand, is ~65°C (35;36) and 
requires formulation with a plasticiser to render it appropriately flexible for use on the skin. 
Unlike the effect of polymer concentration on film formation, the incorporation of plasticisers 
was less easily perceived visually and the release kinetics of BMV proved to be more discrim-
inatory.   
As the principal goal of this work was to identify FFS capable of producing polymer films 
that would release a topical drug over a prolonged period, an in vitro experimental strategy 
was designed using an artificial membrane in an optimised diffusion cell configuration. This 
allowed drug release to be followed over 72 hours, a duration not recommended (for obvious 
reasons) for a study involving excised mammalian skin (37). The artificial membrane chosen 
was silicone, which has been used to investigate drug release from topical formulations and 
offers, at least, a barrier of lipophilic character that is more relevant to that of skin than, for 
example, cellulose acetate (15;38-41). It was also found that the tested polymer films made 
better and more uniform contact with silicone, as compared to cellulose acetate membranes 
(data not shown). It must be emphasised, however, that while the BMV release kinetics re-
ported here are of value for differentiating between the different formulations tested, they are 
not to be considered indicative of their performance when applied to skin. In the latter case, 
the complex interactions of the FFS with the SC as the volatile solvent simultaneously evapo-
rates and penetrates (and possibly enhances absorption of the drug), as well as the evolution 
of the polymeric film with time and the potential, transient supersaturation of BMV (and all 
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coupled with the greater inherent variability of such experiments), add multiple layers of 
complication to the interpretation of the results. A detailed skin absorption study from the FFS 
described here will be reported elsewhere. 
The literature demonstrates that the nature of the polymer influences not only the mechanical 
properties and cosmetic attributes of the formed film (8-10;33;42-44) but also drug release 
therefrom (9;10;15;42;45). In the present study, films prepared from the relatively hydrophilic 
Klucel polymer released significantly more BMV over 72 hours than those formed by the 
more hydrophobic, polyacrylates and polymethacrylates, an observation completely consistent 
with previous findings (15). It has been estimated from in vivo experiments in humans (cf. 
typical bioavailability of topical corticosteroids is a few percent (46)) that conventional semi-
solid formulations of BMV would deliver at least 6 µg/cm2 of drug over 72 hours (based on 
once-daily dosing). Clearly, the Klucel film releases more than enough drug in this period (42 
µg/cm2) to satisfy this goal; in contrast, the hydrophobic films released only about one-tenth 
of that from Klucel, falling just below the ‘target’.   
The higher release of BMV from Klucel relative to the hydrophobic films may well reflect the 
lower solubility of the drug in the former. When formulated at the same concentration in both 
types of polymer, therefore, it is clear that BMV’s “leaving tendency” from Klucel will be 
greater (47;48). This enhanced thermodynamic activity may be further increased by the great-
er water sorption into the Klucel film than that into the polymethacrylates (24% versus 6% for 
Eudragit RS, for example – data not shown; (49;50)). Thus, the preferential uptake of water 
into Klucel will make the polymer an even less sympathetic environment for BMV, the release 
rate of which will be increased. Water has also been proposed as a plasticiser of polymer net-
works (49;51;52), an effect that can reasonably be expected to facilitate drug diffusion within 
the film (8;53). Lastly, should any supersaturation of drug occur during the creation of the 
film as the volatile solvent evaporates(38;39), then it is known that different polymers are able 
to stabilise the resulting metastable state to different degrees (54-56). Whether this contributes 
to the superior release of BMV from Klucel requires further investigation and may offer a 
new strategy for FFS formulation optimisation.  
Incorporation of plasticisers into the polymer films lowers the Tg, improves flexibility on the 
skin and, as mentioned above, is anticipated to increase drug diffusivity within, and hence 
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release from, the film. The mechanism underpinning the effect of plasticisers is believed to be 
via an increase in polymer chain mobility and an associated enhancement of the free volume 
available for drug diffusion (10;57;58). In the case of Eudragit RS, all plasticisers improved 
BMV release and the aim of achieving liberation of 6 μg/cm2 was attained. Drug release ap-
peared to increase fairly linearly with plasticiser lipophilicity (as measured by log P), perhaps 
through an increase in BMV’s solubility in the polymer. For Klucel, the presence of plasticiser 
again improved drug release. The effects of TEC and TBC were comparable while the most 
lipophilic plasticiser (DBS) had the biggest impact on drug release.  
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5 Conclusions 
The research described here demonstrates that drug-loaded polymeric films, of acceptable 
substantivity, flexibility and cosmetic attributes, are capable of sustaining release of an active 
compound over a period of 72 hours. Liberation from a hydrophilic polymeric film was great-
er than that from those made from hydrophobic polymers, as expected for the lipophilic drug 
(BMV, log P ~ 3.6 (59)) involved. Given that the residence time of a water-soluble polymer 
film is unlikely to exceed 8 hours, the rapid transfer of the drug into a “reservoir” in the SC is 
preferred; on the other hand, greater substantivity is anticipated for hydrophobic polymer 
films for which the “reservoir” of drug may also be held on, as well as within, the skin. While 
the incorporation of plasticisers had no obvious effect on the visually-assessed mechanical 
properties of the polymeric films, their presence significantly enhanced drug release, such that 
all the systems studied were able to release the target quantity of drug over a 3-day period. 
The stage is now set for further work to refine the lead formulations and to evaluate their per-
formance in terms of drug delivery into and through the skin. 
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Table 1. Composition of film-forming systems tested for in vitro release; amounts given in 
%w/w 
Formulation constituents 
Polymer Dermacryl Eudragit Eudragit    Klucel    
 79 NE RS    LF    
 10.0 7.5 15.0 15.0 15.0 15.0 5.0 5.0 5.0 5.0 
           
Plasticiser           
DBS    3.0    1.0   
TBC     3.0    1.0  
TEC      3.0    1.0 
           
Solvent           
EtOH 90.0 81.3 80.0 77.0 77.0 77.0 95.0 94.0 94.0 94.0 
Water  11.2 5.0 5.0 5.0 5.0     
DBS= dibutyl sebacate; TBC = tributyl citrate; TEC = triethyl citrate; EtOH = absolute ethanol. 
  
 Page 22 of 27 
 
Frederiksen et al., 2014 submitted to European Journal of Parmaceutics and Biopharmaceutics. 
 
 
 
Figure 1. Illustration of modified diffusion cell experiment. The membrane area, across which 
drug release was measured, was 1.9 cm2.  
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Table 2. Visual evaluation of film-forming systems with varying type and concentration of 
polymer. 
  FFS Formed film 
Polymer  % 
w/
w 
Appear-
ance 
Viscosi-
ty* 
Dry-
ing 
time 
Outward 
sticki-
ness 
Film-
formation 
** 
Cosmet-
ic at-
tributes 
Structur-
al fea-
tures ** 
Flexibil-
ity 
Der-
macryl 
5.0 
Clear 
Low,  
runny 
≤ 5 
min 
Low 
Complete / 
homogene-
ous 
Clear, 
slightly 
glossy 
Smooth 
Flexible 
 
7.5 
Low, 
slightly 
runny 
Non-
flexible 
 10.
0 
Low, 
slightly 
runny 
Non-
flexible 
Eudragit 
NE 5.0 
Clear 
Low, 
slightly 
runny 
7 min 
Low 
Complete / 
homogene-
ous 
Clear, 
slightly 
glossy 
Smooth / 
struc-
tured 
Flexible 
 
7.5 Low 8 min 
Complete / 
homogene-
ous 
Struc-
tured 
Flexible 
 
10.
0 
Medium 9 min 
Film with 
little precip-
itation 
Struc-
tured 
Flexible 
/ non-
flexible 
Eudragit 
RS 
10.
0 
Clear 
Low, 
runny 
≤ 5 
min 
Low 
Complete / 
homogene-
ous 
Clear, 
slightly 
glossy 
Smooth 
Flexible 
/ non-
flexible 
 15.
0 
Low, 
slightly 
runny 
Low Smooth 
Flexible 
/ non-
flexible 
 
20.
0 
Low, 
slightly 
runny 
Medium 
Smooth / 
struc-
tured 
Non-
flexible 
Klucel 
2.5 
Clear 
Low, 
Very 
runny 
≤ 5 
min 
Low 
Complete / 
homogene-
ous 
Clear, 
matt 
Smooth Flexible 
 
5.0 Low 8 min Smooth 
Flexible 
/ non-
flexible 
 
7.5 Medium 
10 
min 
Smooth / 
struc-
tured 
Non-
flexible 
 10.
0 
High 
10 
min 
Struc-
tured 
Non-
flexible 
* Viscosity was also evaluated with regards to controlling its distribution when applied to the skin. ** Evaluation 
also conducted of film formed in a petri dish for better assessment. 
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Table 3. Visual evaluation of film-forming systems with varying type of plasticiser. 
Polymer  Plasticiser Drying time Outward sticki-
ness 
Cosmetic attrib-
utes 
Flexibility 
10% Dermacryl TEC 
≤ 5 min Low 
  
 TBC Clear Non-flexible 
 DBS   
15% Eudragit 
RS 
TEC 
≤ 5 min Low Clear 
 
 TBC Non-flexible 
 DBS  
5% Klucel TEC 
6 min Low 
Clear Flexible 
 
TBC 
Transparent, 
slightly hazy 
Flexible / non-
flexible 
 
DBS 
Transparent, 
slightly hazy 
Non-flexible 
DBS= dibutyl sebacate; TBC = tributyl citrate; TEC = triethyl citrate. * Evaluation also conducted of film 
formed in a petri dish for better assessment. 
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Figure 2. In vitro release profiles of BMV from polymeric film-forming systems (mean ± 
standard deviation; n=3). Upper panel: Klucel. Lower panel: Hydrophobic polymers. 
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Figure 3. In vitro release profiles of BMV from Klucel (upper panel) and Eudragit RS (lower 
panel) film-forming systems with and without plasticisers (mean ± standard deviation; n = 2 
or 3). 
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Figure 4. Kinetics of BMV release rate from Klucel and Eudragit RS polymer films as a func-
tion of the lipophicility (measured by log P) of three plasticisers (TEC, log P = 1.3; TBC, log 
P = 4.3; DBS, log P = 6.0) incorporated into the formulations at 20% w/w. The left-hand axis 
plots the zero-order release rates from the Klucel films (open squares), the right-hand axis 
plots the square-root of time kinetics from the Eudragit systems (filled triangles). Log P val-
ues from SciFinder, calculated using Advanced Chemistry Development (ACD/Labs) Soft-
ware V11.02 (© 1994-2014 ACD/Labs). 
